Freedom of Information request on the Public Assessment Report for Cibinqo 50, 100 & 200 mg film-coated tablets (FOI 21/1211)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-6-december-2021/freedom-of-information-request-on-the-public-assessment-report-for-cibinqo-50-100-200-mg-film-coated-tablets-foi-211211
FOI 21/1211
12th December 2021
Dear
Thank you for your email of 11 November 2021, where you requested the Public Assessment Report (PAR) for the product Cibinqo (abrocitinib) 50, 100 & 200 mg film-coated tablets (PLGB 00057-1703-05).
The PAR is not currently available. However, we anticipate a PAR will be published for the above procedure in the next 4 to 6 weeks. For this reason, we are exempting providing the PAR under Section 22 of the Freedom of Information (FOI) Act (information intended for future publication), as we intend to publish this PAR in the next 4 to 6 weeks. Section 22 is a qualified exemption and a consideration of the public interest is necessary, We have considered the public interest and cannot see any reason why a version of the PAR should be provided under the FOI Act before it is ready to be published on the MHRA website.
If you have a query about the information provided, please reply to this email.
Yours sincerely,
Customer Services